PTAB must bite bullet and make definitive call on hedge fund inter partes review requests
Inter partes review requests make up only a small part of the Patent Trial and Appeal Board’s workload; but they are causing it a major headache. That will continue for as long as it avoids addressing the issue head on
On September 1 the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) declined to institute a petition for the inter partes review of US Patent 8,399,514, owned by Biogen. It had been requested by the Coalition for Affordable Drugs, an organisation established by hedge fund investor Kyle Bass and IPNav founder Erich Spangenberg.
Want to read more?
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Straight talk on key IP issues, IAM aims to provide executive managers with the business perspective that often gets lost in technical jargon and legal details.
Senior vice president of intellectual property
The Nielsen Company
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.